DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor and positive impact of reference anti-HER2 treatment on overall survival

DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor and positive impact of reference anti-HER2 treatment on overall survival

Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 10, 2020 /PRNewswire/ -- Menarini Silicon Biosystems, a...

Read more: DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cance...

More Articles …

  1. Amid the Global Crisis, UNDP and Mohammed bin Rashid Al Maktoum Knowledge Foundation (MBRF) Launch Global Knowledge Index 2020-PR Newswire APAC
  2. Infosys Accelerates Enterprise Modernization Journey to the Cloud with the Infosys Modernization Suite-PR Newswire APAC
  3. Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG-PR Newswire APAC
  4. Bruce Rock Engineering Unveils New Super Quad with SSAB's New Wear Steel-PR Newswire APAC
  5. ActLight expands its IP portfolio with the launch of the Stand-Alone Dynamic PhotoDiode
  6. A plan to address fossil fuels is key for the Climate Ambition Summit
  7. Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals
  8. Thunderhead expands APAC footprint with hire of industry thought leader Aarron Spinley, VP ANZ
  9. Welsh Developments ACTC Pty Ltd Announces Offering of AUD 142,726,327 Senior Secured Loan Note Offer
  10. Adyen to partner with Hungry Jack's to improve its customer service with payment-led updates